Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 13/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.36 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.35 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.35 |
| ▸ | NT5E | P21589 | 1/20 | 0.34 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.34 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.34 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30002219 | 0.91 | TYMP (0.56) | TYMPADORA1 | |
| SCHEMBL9218371 | 0.87 | TYMP (0.44) | TYMPADORA1CDK5CDK5R1 | |
| SCHEMBL313848 | 0.86 | TYMP (0.36) | TYMP | |
| SCHEMBL9221377 | 0.85 | TYMP (0.38) | TYMPADORA1CDK5CDK5R1 | |
| SCHEMBL26781527 | 0.83 | TYMP (0.44) | TYMPADORA1CDK5CDK5R1NT5E | |
| SCHEMBL14665048 | 0.82 | TYMP (0.59) | TYMPADORA1NT5E | |
| SCHEMBL1064717 | 0.82 | TYMP (0.59) | TYMPADORA1NT5E | |
| SCHEMBL1081208 | 0.82 | TYMP (0.47) | TYMPADORA1NT5E | |
| SCHEMBL5963136 | 0.81 | TYMP (0.52) | TYMPCDK5CDK5R1 | |
| SCHEMBL5963086 | 0.81 | TYMP (0.54) | TYMPADORA1CDK5CDK5R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220288100-A1 | 2'-METHOXY SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS | IONIS PHARMACEUTICALS, INC. (US) | 2022-09-15 | — | — | US | disclosed |
| EP-4039807-A1 | ANTISENSE OLIGONUCLEOTIDES USEFUL IN TREATMENT OF POMPE DISEASE | Erasmus University Rotterdam Medical Center (NL) | 2022-08-10 | — | — | EP | disclosed |
| US-20220162603-A1 | COMPOSITIONS COMPRISING ALTERNATING 2'-MODIFIED NUCLEOSIDES FOR USE IN GENE MODULATION | IONIS PHARMACEUTICALS, INC. (US) | 2022-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220162603-A1 | COMPOSITIONS COMPRISING ALTERNATING 2'-MODIFIED NUCLEOSIDES FOR USE IN GENE MODULATION | NSUN2, RNMT, NSUN3 | TYMP 800/4885ADORA1 2142/4885CDK5 1415/4885 |
| US-20220288100-A1 | 2'-METHOXY SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS | NSUN2, SNRPE, RBM3 | TYMP 2606/4885ADORA1 4428/4885CDK5 2291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.